Determining the Microbiota Composition of the Middle Meatus in Parkinson's
Determining the Microbiota Composition of the Middle Meatus in Parkinson's Disease
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Kontakter og lokationer
Studiesteder
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60612
- Rush University Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- 1. Patients with a clinical diagnosis of Parkinson's disease by United Kingdom Parkinson Disease Society Brain Bank criteria will be recruited.
2. Hoehn & Yahr stage 1-3 3. Parkinson's disease symptomatic treatment will be allowed. 4. Subjects with deep brain stimulation are allowed.
Exclusion Criteria:
1. Occupation expected to change intestinal flora pattern (e.g. sanitation worker) 2. Treatment with medications that may induce parkinsonism (metoclopramide, typical, or atypical antipsychotic agents) 3. Treatment within 12 weeks with systemic antibiotics 4. Known diagnosis of inflammatory bowel disease 5. Symptomatic organic GI disease other than hemorrhoids and hiatal hernia or abdominal surgeries for symptomatic GI disease such as bowel resection, diverticular surgery, colostomy, etc (subjects with a history of an appendectomy or cholesytectomy for benign disease more than 5 years prior to presentation are allowed).
6. Symptomatic functional GI disease that significantly impairs intestinal motility such as scleroderma or use of GI motility drugs 7. Acute illness requiring immediate hospitalization 8. Pre-existent organ failure or comorbidities as these may change GI flora:
- Liver disease (cirrhosis or persistently abnormal AST or ALT that are 2X> normal);
- Kidney disease (creatinine>2.0 mg/dL);
- Uncontrolled psychiatric illness;
- Clinically important lung disease or heart failure;
- HIV disease;
- Alcoholism, unreliable drinking history; or consumption of alcohol more than 3 times a week or binge drinking or drinking more than or equal to 3 drinks per occasion;
- Transplant recipients;
- Diabetes;
- Clinically significant dehydration or clinically detectable ascites or peripheral edema or cardiac failure 9. Presence of short bowel syndrome or severe malnutrition with ideal body weight < or = 90% or 10. Estimated survival <1 year and Karnofsky performance status <50%; 11. Use of immunosuppressive medications within 3 months of enrollment 12. Chronic use of diuretics
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Parkinson's disease subjects
Patients with untreated or treated Parkinson's disease ages 45-75.
|
a nasal swab will be performed by a trained physician by gently passing of a cotton swab in the nasal passage to get samples from middle meatus.
This will be performed under guide of nasal anterior endoscopy to visualize the location of sampling.
The cotton swab heads will be placed in sterile tubes and frozen at -80°C until DNA extraction.
|
|
Healthy control subjects
Healthy control subjects ages 45-75.
|
a nasal swab will be performed by a trained physician by gently passing of a cotton swab in the nasal passage to get samples from middle meatus.
This will be performed under guide of nasal anterior endoscopy to visualize the location of sampling.
The cotton swab heads will be placed in sterile tubes and frozen at -80°C until DNA extraction.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
nasal inflammatory microbiome
Tidsramme: 1 year
|
For microbiome analysis, in silico community functional predictions will be performed using PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of Unobserved States) and significant differences in Kyoto Encyclopedia of Genes and Genomes (KEGG) ortholog (KO) abundances between groups will be identified.
"proinflammatory" and "anti-inflammatory" bacteria taxa will be classified and differences in inflammatory metabolite abundance will be compared.
|
1 year
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 16111609-IRB01
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Parkinsons sygdom
-
NCT07277699Afsluttet
-
NCT02305277Afsluttet
-
NCT07217054RekrutteringParkinsons sygdom | Parkinson | PARKINSON SYGGE (lidelse) | Parkinsons sygdom
-
NCT07289477RekrutteringEn fase I/III klinisk undersøgelse til evaluering af NouvNeu001-injektion til multippel systematrofiMultipel systematrofi - Parkinson subtype (MSA-P)
-
NCT07402928RekrutteringSund og rask | Parkinson | Administration af medicin
-
NCT07148700RekrutteringParkinsons sygdom | Parkinson | Parkinsons sygdom (PD) | PARKINSON SYGGE (lidelse) | Parkinsons sygdom
-
NCT07204652RekrutteringParkinsons sygdom | Parkinson | Parkinsons sygdom og Parkinsonisme | PARKINSON SYGGE (lidelse)
Kliniske forsøg med Nasal swab
-
NCT07192315Ikke rekrutterer endnuSolid kræft | Maligniteter i faste tumorer
-
NCT07484256Rekruttering
-
NCT07106944Ikke rekrutterer endnuTransport af ESBL-positiv Escherichia coli | Transport af ESBL-positiv Klebsiella pneumoniae
-
NCT06951438RekrutteringKlamydia | Gonoré | Trichomonas infektion | Seksuelt overført sygdom (STD)
-
NCT06472765Tilmelding efter invitationKræft | Candidiasis | Endometriose | Urinvejsinfektioner | Lav Planus | Lichen Sclerosus | Bakteriel vaginose | Vulvodyni | Genitourinært syndrom i overgangsalderen | Desquamativ inflammatorisk vaginitis
-
NCT03676816AfsluttetChlamydia Trachomatis | Neisseria Gonorrhoeae
-
NCT01499238UkendtForbigående takypnø hos nyfødt
-
NCT05921396RekrutteringNasal obstruktion | Hypofyse adenom Invasiv
-
NCT06817499Aktiv, ikke rekrutterende
-
NCT07252102RekrutteringLevercirrhose | Gastrointestinal dysfunktion | Polypper af tyktarm